Downloading...
Download

Pharmasector

Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
Ironwood Pharmaceuticals | IRWD | Long at $0.61Ironwood Pharma NASDAQ:IRWD stock dropped ~89% in the past year due to disappointing Phase 3 Apraglutide trial results, FDA requiring an additional trial, weak Q1 2025 earnings (-$0.14 EPS vs. -$0.04 expected), high debt ($599.48M), and analyst downgrades. So why would I be interested in swing trading this company? The chart. The price has entered my "crash" simple moving average zone, which often results in a reversal - even if temporary. Also, Linzess (GI drug) revenue is steady, and I thoroughly believe that alone pushes the fair value near $0.95, if not higher. Thus, at $0.61, NASDAQ:IRWD is in a personal buy zone with the potential for additional declines before future rise. Target: $0.95 (+55.7%)
NASDAQ:IRWDLong
by WorthlessViews
The Collaborative Edge: Pfizer's Innovation Secret? Pfizer's success in the biopharmaceutical industry hinges on its internal capabilities and a strategic embrace of external collaboration. This proactive approach, spanning diverse technological frontiers, fuels innovation across its operations. From partnering with QuantumBasel and D-Wave to optimize production planning using quantum annealing, to collaborating with XtalPi to revolutionize drug discovery through AI-powered crystal structure prediction, Pfizer demonstrates the tangible benefits of cross-industry partnerships. These initiatives showcase a commitment to exploring cutting-edge technologies to enhance efficiency and accelerate the identification of promising drug candidates, ultimately improving patient outcomes and strengthening Pfizer's competitive position. The article highlights specific examples of Pfizer's collaborative endeavors. The Pfizer Healthcare Hub in Freiburg acts as a catalyst, connecting internal needs with external innovation. The successful proof of technology in production planning using quantum annealing resulted in significant time and resource savings. Furthermore, the partnership with XtalPi has dramatically reduced the timeframe for determining the 3-D structure of potential drug molecules, enabling faster and more efficient drug screening. These collaborations exemplify Pfizer's strategic focus on leveraging specialized expertise and advanced technologies from external partners to overcome complex challenges in the pharmaceutical value chain. Beyond these specific projects, Pfizer actively engages with the broader quantum computing landscape, recognizing its transformative potential for drug design, clinical studies, and personalized medicine. Collaborations with technology giants like IBM and fellow pharmaceutical companies underscore the industry-wide interest in harnessing the power of quantum computing. While the technology is still in its early stages, Pfizer's proactive participation in this collaborative ecosystem positions it at the forefront of future healthcare breakthroughs. This commitment to synergy, from basic research to market research, underscores a fundamental belief in the power of working together to drive meaningful advancements in the pharmaceutical industry.
NYSE:PFELong
by UDIS_View
Globus Medical: Approaching resistance, is a breakthrough comingWeekly Chart ● The stock has tested the trendline resistance multiple times. ● Currently, it is trading just below this level. ● A breakout above this resistance is anticipated in the near future. ● Following the breakout, the price may increase. Daily Chart ● A Symmetrical Triangle pattern has formed. ● A strong breakout has taken place, supported by significant volume. ● The price is now set for a potential upward movement.
NYSE:GMEDLong
by NaranjCapital
S&P Pharmaceutical Sector: A Prescription for Growth● The S&P Pharmaceutical sector has great potential for growth. ● The weekly chart shows that after breaking out of the Symmetrical Triangle Pattern, the ETF had a short period of consolidation and is now ready for a rise. ● The daily chart also indicates a Cup & Handle Pattern, with the price trending upward post-breakout. As the industry revives, certain stocks are ready to achieve similar success Key stocks to watch: Hims & Hers NYSE:HIMS ● The price has broken the trendline resistance with high volume. ● More upward movement is likely to follow. Crinetics Pharmaceuticals NASDAQ:CRNX ● Mirrors HIMS' chart pattern. ● Poised for robust growth after breakout.
AMEX:XPHLong
by NaranjCapital
Index to watchout for next week: Pharma Index. For the past few weeks we have been trying to understand how to use the performance of an index reflects in performance of stocks that are constituents of that particular index and vice versa. By catching the index that is on the verge of breaking out or has broken out during the week, we can plan our investment and trades around it to maximize our returns. We spoke about Bank Nifty, then IT Index. Both gave considerable returns in the last 2 /3 weeks. The index that look most interesting this week end is Pharma Index. Pharma index has given a powerful breakout and has closed above very important fibonacci resistance (20380) this week. The closing of Pharma index this week was 20453.85. The next 2 Fibonacci resistances for Nifty will be at 21013 and 21475. Supports for the Pharma index remain at 19936 and 19397. 19397 is a mega support which has a combined power of Fibonacci, Mid-channel and 50 days EMA. The stocks that constitute the Pharma index are: Lupin, Dr.Reddy's Lab, Torrent Pharma, Alkem Lab, Biocon, Divi's Lab, Sun Pharma, Cipla, Zydus Life and Aurobindo Pharma. Some Peripheral Pharma stocks can also be looked at for investment purpose. We are not giving a buy or sell call on any of these companies. This is just an educational article explaining the potential moves of Pharma Index, how it can move in either direction and what can be the technical reasons behind the same. Disclaimer: There is a chance of biases including confirmation bias, information bias, halo effect and anchoring bias in this write-up. Investment in stocks, derivatives and mutual funds is subject to market risks, please consult your investment advisor before taking financial decisions. The data, chart and other information provided above is for the purpose of analysis and is purely educational in nature. The names of the stocks or index levels mentioned in the article are for the purpose of education and analysis only. Purpose of this article is educational. Please do not consider this as a recommendation of any sorts.
NSE:CNXPHARMALong
by Happy_Candles_Investment
GLENMARK : ALL TIME HIGH BREAKOUT / CUP BREAKOUTGLENMARK is currently trading around its all-time high (ATH) and presents an opportunity for a long trade with a promising risk-reward profile. The strategy involves entering a position at 4% above the ATH and employing a dynamic stop-loss approach to manage risk and maximize potential gains. Entry: Enter a long position at GLENMARK's ATH price + 4% (1,313.40) Initial Stop-Loss: Set an initial stop-loss at 20% below the entry price (1,050.70) or Weekly Swing Low. Targets: First Target: 1,913.45 (Fibonacci 1.618 level) Second Target: 2,364.15 (Fibonacci 2 level) Third Target: 3,465.40 (Fibonacci 3 level) Position Sizing: Limit the trade size to ensure that no more than 5% of your capital is at risk. In case the stop-loss is triggered, the maximum capital loss will be limited to 1% The dynamic stop-loss adjustment after reaching the first target further protects capital and locks in profits. The position sizing ensures that you are not risking more than you can afford to lose. Disclaimer: This trading strategy is for informational and educational purposes only and should not be construed as financial advice. Please conduct your own research and due diligence before making any trading decisions. Additional Notes: Consider using technical indicators and chart patterns to refine your entry and exit points. Monitor market conditions and adjust your strategy accordingly. Practice risk management techniques to protect your capital. Please let me know if you have any other questions.
NSE:GLENMARKLong
by lalitcpanchal
The Rising Sun - SOLARA ACTIVE PHARMASolara Active Pharma went thru a Turmoil after its Ex-CEO resigned almost 2 years ago citing reasons for his failure to manage the company's profitability After the new management took charge - it took 18+ months to stabilize and now to turn the stock to Bullish mode. Technical Pattern: On Weekly - Solara BO of a Falling Wedge Pattern from Jun 2022, but after BO it faced major resistance at 450 levels forcing it go down and Retest the BO zone After Successful Retesting, the price took a strong Bullish Reversal and today trading approx 11% higher and testing the 450 zone again. This time, it has formed a Strong Rounding Bottom Pattern. A strong BO above 450 WCB will take the stock to 550 levels quickly, but this is not the end - there is much more distance to Cover for Solara the subsequent targets given at 840, 1200++. Its a Multi-bagger in the making. Don't miss out this Master Blaster Disclaimer: 3+ Years Teaching Experience in Stock Market - Technical Analysis, Advanced Patterns, Emotional Management, News based Trading... We are NOT SEBI Registered and Our focus is NOT providing Buy/Sell Recommendations/calls. Primary Objective is to provide detailed analysis of how to review a chart, explain multi-timeframe views purely for Educational Purposes. We strongly suggest our followers to "Learn to Ride the Tide irrespective of its Side" *** Important *** Consult your Financial Advisors before taking any positions If you like our detailed analysis, please do rate us with your Likes, Boost and share your comments -Team Stocks-n-Trends
NSE:SOLARALong
by Stocks-n-Trends
1
Solara - The Sun is Rising Behind the PyramidSolara Active Pharma: After the CEO of Solara resigned 1.5 years ago, the Company shares faced a major crash - retracing near 100% on Fib scale. A large Pyramid like structure was formed eventually Over the past few months - the price has started to strengthen the base taking support near the 290-300 zone which is one the Strongest support for the script A Bullish Reversal sign is seen when a Right Angled Triangle pattern was formed and successfully breaking out of the Pattern along with the next immediate resistance at 410. I can also be seen as a Double Bottom pattern - long long way to go Its changing direction from being a Sunset company to a Sunrise company. With the Breakout of Pharma sector, many Pharma companies are having their dream run and SOLARA is riding the journey along with its peers. The Sun is Rising behind the Tall Pyramid. Wait for Large Targets ahead - 550, 830, 1200 Disclaimer: Stocks-n-Trends is NOT a SEBI registered company. We do not provide Buy / Sell recommendations - rather we provide detailed analysis of how to review a chart, explain multi--timeframe views purely for Educational Purposes. We strongly suggest our followers to "Learn to Ride the Tide" and consult your Financial Advisors before taking any positions. If you like our detailed analysis, please do rate us with your Likes, Boost and share your comments -Team Stocks-n-Trends
NSE:SOLARALong
by Stocks-n-Trends
Pharma Sector and its components Daily Timeframe AnalysisPharma Sector and its components are in correction phase NSE:CNXPHARMA sectors NSE:DIVISLAB , NSE:SUNPHARMA , NSE:DRREDDY have created same structure as NSE:NIFTY NSE:DIVISLAB , NSE:SUNPHARMA , NSE:DRREDDY daily candle close below level. We can see all targets along with NSE:NIFTY , $NSE:CNXMETAL. Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
NSE:CNXPHARMAShort
by sugatmankar
Merck: Water slide 🛝The pool-season is about to start, and Merck has already secured its place on the water slide, which should take it further downwards below the support at $110.66. However, there is still a 35% chance that the share might catch a bubbling fountain which could push it above the resistance at $119.65. In that case, we would expect Merck to develop a new top in the form of wave alt.B in green in the green zone between $119.87 and $123.79 first before turning downwards again.
NYSE:MRK
by MarketIntel
Pharma Stock Alert: NSE:CAPLIPOINT Ready to BreakoutHello, fellow traders! Today, we are going to look at NSE:CAPLIPOINT, a pharma sector stock that is ready to breakout. The NSE:CNXPHARMA broke its resistance in October and showed signs of going higher, but it has been consolidating for four months now. Looking at the chart, we can see that the price is patiently approaching the mentioned price level, and the entry price for this stock is also at a bottom level. This presents a great opportunity for a long position in this stock, making it an ideal trading system. Remember, the price is the "King of Market," and we cannot guarantee anything in the market. This view is for educational purposes only, and any stock mentioned here should not be taken as trading or investing advice. Please consult your financial advisor before investing, and always remember to manage your risk. Thanks & regards, Alpha Trading Station.
NSE:CAPLIPOINTLong
by AlphaTradingStation
2
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year) Its Financial Health is very strong. Why not wait till Moderna makes greater progress and finds It Resistance Again at $450 Moderna has many projects running. So if we see progress in some of the projects in the next Years, we will see a great price rise. I believe it won't be difficult to reach its older resistance again, around $450. Disclaimer: Just my Idea! Find your Trading Ideas and learn and study more!
NASDAQ:MRNALong
by TraderMentorX
AUROPHARMA Bounced off Demand zone. Go Long accordinglyHello Guys the Market have been Quite a good ride in the previous week and it was fun. Last target of 10% in MAXHEALTH was hit in one day. Now Auropharma was in a downtrend/correction phase for some time and now has reached a strong Demand Zone(Daily, Weekly, Monthly) and took a good >10% bounced of it and is making HH & HL in smaller timeframes. Now consolidating in a channel which is a bullish channel and I expect big upmove after the break of channel. RSI has room for Bulls. MACD is retreating from bearish side and now going towards bullish. Demand zone bounce has already been confirmed. BUY ABOVE - 687 Targets mentioned in the chart. Manage your positions, Risk reward is good. Please LIKE, COMMENT and SHARE to motivate and support me. I'll keep on posting new ideas on Indices & Stocks. Be sure to follow so that you don't miss any good trades that might have been rewarding. Any comments and critiques will be appreciated even if it's of opposite view as a trader can also be right so many times.
NSE:AUROPHARMALong
by this_is_shoaib
4